Tumor Ag-specific CD8+ T cells bearing with long telomeres are optimal in ACT-based therapies because these CD8+ T cells have better proliferation, survive for longer than short-telomere cells and have a greater response to homeostatic cytokines. Here, CD8A is linked to neoplasm.